SuperworthEnsysce Biosciences EPS ENSC
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$2.76
- Latest quarter, Q2 FY26
- −$0.20
- Fiscal year 2025
- −$4.22
Ensysce Biosciences' earnings per share was −$2.76 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.20.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.22 | n/a |
| FY2024 | −$13.46 | n/a |
| FY2023 | −$79.05 | n/a |
| FY2022 | −$6443.40 | n/a |
| FY2021 | −$4590.00 | −498% |
| FY2020 | $1152.00 | n/a |
| FY2019 | −$1800.00 | n/a |
| FY2018 | −$720.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.20 | n/a | −$2.76 | |
| Q1 FY26 | −$0.52 | n/a | −$3.35 | |
| Q4 FY25 | −$0.75 | n/a | −$4.22 | |
| Q3 FY25 | −$1.29 | −229% | −$6.37 | |
| Q2 FY25 | −$0.79 | n/a | −$4.08 | |
| Q1 FY25 | −$1.39 | n/a | −$6.64 | |
| Q4 FY24 | −$2.90 | n/a | −$13.46 | |
| Q3 FY24 | $1.00 | n/a | −$30.66 | |
| Q2 FY24 | −$3.35 | n/a | −$44.71 | |
| Q1 FY24 | −$8.21 | n/a | −$56.06 | |
| Q4 FY23 | −$20.10 | n/a | −$79.05 | |
| Q3 FY23 | −$13.05 | n/a | −$333.45 |
Against its peers
Companies in Drug Manufacturers - General nearest Ensysce Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ENSCEnsysce Biosciences | −$2.76 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Ensysce Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.